Truist Securities Upgrades NovoCure Ltd. (NVCR) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts NVCR Hot Sheet
Price: $13.43 +1.67%
Rating Summary:
11 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Rating Summary:
11 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Join SI Premium – FREE
Truist Securities analyst Gregory Fraser upgraded NovoCure Ltd. (NASDAQ: NVCR) from Hold to Buy.
For an analyst ratings summary and ratings history on NovoCure Ltd. click here. For more ratings news on NovoCure Ltd. click here.
Shares of NovoCure Ltd. closed at $64.18 yesterday.
You May Also Be Interested In
- ICICI Securities Upgrades Central Depository Services India Ltd (CDSL:IN) to Hold (3)
- Scotiabank Upgrades ERO Copper (ERO:CN) (ERO) to Sector Outperform
- NovoCure Ltd. (NVCR) PT Lowered to $15 at Wells Fargo
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
